Snapshot from Sep 11, 2026 at 07:00 UTC. For live data and tracking: View Live
Company

Sarepta Therapeutics

Tracked across 3 events · 119 articles · First seen Aug 19, 2026 · Last active Sep 08, 2026

Sentiment
-23
Attention
6
Events
3
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
4 -60
Business
On September 8, 2026, Novartis announced that the Phase III HARBOR study of del-desiran (delpacibart etedesiran) in myotonic dystrophy type 1 (DM1) did not meet its primary endpoint of video hand opening time (vHOT). The…
Impact: Shares fell about 11-15.5% in premarket trading due to negative read-through from Novartis failure.
Sep 08, 2026 · 12 articles
6 -10
Domestic
Impact: Sarepta Therapeutics, a biotech, had public disagreements with the FDA. The new commissioner's approach could impact its drug reviews.
Aug 19, 2026 · 101 articles
4 0
Regulatory
The U.S. Department of Health and Human Services is planning to create two new deputy commissioner roles at the United States — Food and Drug Administration, one focused on technology and artificial intelligence and the…
Impact: Sarepta was mentioned as having public disagreements with the FDA under Makary, but no recent action is noted.
Aug 25, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Sarepta Therapeutics live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.